TenNor Therapeutics Launches Up to HK$627 Million Hong Kong IPO

MT Newswires Live

05/14

TenNor Therapeutics (HKG:6872) launched its Hong Kong initial public offering on Thursday, seeking to raise about HK$626.8 million from the deal.

The China-based near-commercial stage biotechnology company is offering 8.3 million shares at HK$75.70 each, according to a Hong Kong bourse filing.

The offering comprises 828,100 shares for Hong Kong investors and 7.5 million shares for international investors, subject to reallocation, the offer size adjustment option, and the overallotment option.

Allocation results are due by May 21, ahead of the company's planned trading debut on May 22.

Net proceeds will be used mainly to fund the research, development, regulatory filings, and commercialization of core products rifasutenizol and rifaquizinone injection.

The funds will also be used to support clinical development of TNP-2092, advance other pipeline candidates, construct an in-house manufacturing facility in Guangdong, and for working capital and general corporate purposes.

CITIC Securities (Hong Kong) and ABCI Capital are acting as joint sponsors.

CLSA and ABCI Capital are serving as sponsor-overall coordinators, overall coordinators, and joint global coordinators, while also acting as joint bookrunners alongside China Renaissance Securities (Hong Kong).

CLSA, ABCI Securities Company, China Renaissance Securities (Hong Kong), Futu Securities International (Hong Kong), and Tiger Brokers (HK) Global are acting as joint lead managers.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2635763799"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2635763799\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2635763799?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-14 10:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2635763799","market":"us","top_or_hot":-1,"title":"TenNor Therapeutics Launches Up to HK$627 Million Hong Kong IPO","media":"MT Newswires Live","content":"<html><body><p> TenNor <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (HKG:6872) launched its Hong Kong initial public offering on Thursday, seeking to raise about HK$626.8 million from the deal.</p><p>The China-based near-commercial stage biotechnology company is offering 8.3 million shares at HK$75.70 each, according to a Hong Kong bourse filing.</p><p>The offering comprises 828,100 shares for Hong Kong investors and 7.5 million shares for international investors, subject to reallocation, the offer size adjustment option, and the overallotment option.</p><p>Allocation results are due by May 21, ahead of the company's planned trading debut on May 22.</p><p>Net proceeds will be used mainly to fund the research, development, regulatory filings, and commercialization of core products rifasutenizol and rifaquizinone injection.</p><p>The funds will also be used to support clinical development of TNP-2092, advance other pipeline candidates, construct an in-house manufacturing facility in Guangdong, and for working capital and general corporate purposes.</p><p>CITIC Securities (Hong Kong) and ABCI Capital are acting as joint sponsors.</p><p>CLSA and ABCI Capital are serving as sponsor-overall coordinators, overall coordinators, and joint global coordinators, while also acting as joint bookrunners alongside <a href=\"https://laohu8.com/S/CSCHF\">China Renaissance</a> Securities (Hong Kong).</p><p>CLSA, ABCI Securities Company, China Renaissance Securities (Hong Kong), Futu Securities International (Hong Kong), and Tiger Brokers (HK) Global are acting as joint lead managers.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TenNor Therapeutics Launches Up to HK$627 Million Hong Kong IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTenNor Therapeutics Launches Up to HK$627 Million Hong Kong IPO\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2026-05-14 10:06</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> TenNor <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (HKG:6872) launched its Hong Kong initial public offering on Thursday, seeking to raise about HK$626.8 million from the deal.</p><p>The China-based near-commercial stage biotechnology company is offering 8.3 million shares at HK$75.70 each, according to a Hong Kong bourse filing.</p><p>The offering comprises 828,100 shares for Hong Kong investors and 7.5 million shares for international investors, subject to reallocation, the offer size adjustment option, and the overallotment option.</p><p>Allocation results are due by May 21, ahead of the company's planned trading debut on May 22.</p><p>Net proceeds will be used mainly to fund the research, development, regulatory filings, and commercialization of core products rifasutenizol and rifaquizinone injection.</p><p>The funds will also be used to support clinical development of TNP-2092, advance other pipeline candidates, construct an in-house manufacturing facility in Guangdong, and for working capital and general corporate purposes.</p><p>CITIC Securities (Hong Kong) and ABCI Capital are acting as joint sponsors.</p><p>CLSA and ABCI Capital are serving as sponsor-overall coordinators, overall coordinators, and joint global coordinators, while also acting as joint bookrunners alongside <a href=\"https://laohu8.com/S/CSCHF\">China Renaissance</a> Securities (Hong Kong).</p><p>CLSA, ABCI Securities Company, China Renaissance Securities (Hong Kong), Futu Securities International (Hong Kong), and Tiger Brokers (HK) Global are acting as joint lead managers.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06872","symbol_name":"丹諾醫藥-B","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2635763799","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2635763799","pubTimestamp":1778724388,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"TenNor Therapeutics  launched its Hong Kong initial public offering on Thursday, seeking to raise about HK$626.8 million from the deal.The China-based near-commercial stage biotechnology company is offering 8.3 million shares at HK$75.70 each, according to a Hong Kong bourse filing.The offering comprises 828,100 shares for Hong Kong investors and 7.5 million shares for international investors, subject to reallocation, the offer size adjustment option, and the overallotment option.Allocation results are due by May 21, ahead of the company's planned trading debut on May 22.Net proceeds will be used mainly to fund the research, development, regulatory filings, and commercialization of core products rifasutenizol and rifaquizinone injection.The funds will also be used to support clinical development of TNP-2092, advance other pipeline candidates, construct an in-house manufacturing facility in Guangdong, and for working capital and general corporate purposes.CITIC Securities  and ABCI Capi","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06872":"丹诺医药-B","BK4139":"生物科技","IPOS":"Renaissance International IPO ETF","LENZ":"Therapeutics","BK4007":"制药","SPCX":"SPAC and New Issue ETF","BK4539":"次新股"},"translate_title":"TenNor Therapeutics最多6.27亿港元香港IPO","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1.5,"06872":1,"SPCX":1.5,"IPOS":1.5},"content_text":"TenNor Therapeutics (HKG:6872) launched its Hong Kong initial public offering on Thursday, seeking to raise about HK$626.8 million from the deal.The China-based near-commercial stage biotechnology company is offering 8.3 million shares at HK$75.70 each, according to a Hong Kong bourse filing.The offering comprises 828,100 shares for Hong Kong investors and 7.5 million shares for international investors, subject to reallocation, the offer size adjustment option, and the overallotment option.Allocation results are due by May 21, ahead of the company's planned trading debut on May 22.Net proceeds will be used mainly to fund the research, development, regulatory filings, and commercialization of core products rifasutenizol and rifaquizinone injection.The funds will also be used to support clinical development of TNP-2092, advance other pipeline candidates, construct an in-house manufacturing facility in Guangdong, and for working capital and general corporate purposes.CITIC Securities (Hong Kong) and ABCI Capital are acting as joint sponsors.CLSA and ABCI Capital are serving as sponsor-overall coordinators, overall coordinators, and joint global coordinators, while also acting as joint bookrunners alongside China Renaissance Securities (Hong Kong).CLSA, ABCI Securities Company, China Renaissance Securities (Hong Kong), Futu Securities International (Hong Kong), and Tiger Brokers (HK) Global are acting as joint lead managers.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}